SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently a focal point for investors debating its status as a deeply undervalued fintech leader versus a long-term value trap, as the community intensely scrutinizes the company's aggressive share buyback strategy and potential for AI-driven margin expansion. While significant buyout rumors and strategic partnerships continue to drive speculative interest, sentiment remains sharply divided between those accumulating shares at historic lows and frustrated shareholders demanding more decisive leadership to overcome sustained price stagnation.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is experiencing heightened volatility and trading momentum driven by a strong quarterly earnings report that exceeded expectations and a growing community narrative linking the company to the upcoming SpaceX IPO. Investors are actively debating the company's path to profitability and potential for a short squeeze, while long-term supporters emphasize its critical role as a manufacturing supplier for aerospace and defense leaders.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is capturing investor attention following positive Phase 1 data for its subcutaneous Briumvi treatment in Myasthenia Gravis, which the community sees as a significant expansion of the drug's addressable market. Market participants are actively discussing the potential for a major buyout, with long-term investors pointing to strong commercial execution and upcoming clinical milestones as catalysts for a re-rating of the stock.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust (SLV) is currently experiencing high volatility as investors grapple with complex macroeconomic factors, including shifting inflation data and ongoing geopolitical uncertainties. The community remains deeply divided, with many traders debating whether the current price action represents a temporary correction or a long-term accumulation opportunity for silver’s critical role in AI and industrial sectors.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is seeing active community debate as investors weigh strong economic data and the potential for a small-cap breakout against the risk of persistent interest rate pressure. Traders are focused on volatility ahead of upcoming macroeconomic updates, with many actively hedging against a potential correction while others look for signs of a market rotation into smaller-cap names.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is experiencing significant intraday volatility driven by geopolitical tensions in the Strait of Hormuz and anticipation surrounding upcoming inflation data. The market community is actively debating whether the recent price swings indicate a sustained downturn or if coordinated interventions and algorithmic activity are creating a 'buy the dip' trap for retail traders.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant downward pressure as investors grapple with broad market volatility and concerns over AI-related capital expenditure debt. Despite analyst optimism and bullish sentiment regarding the company's cloud infrastructure backlog, the community remains divided between those panic-selling and others aggressively buying the dip ahead of upcoming earnings.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is experiencing intense intraday volatility as investors react to escalating geopolitical tensions in the Middle East and uncertainty surrounding the upcoming CPI data. Community discussion is heavily divided between bears pointing to a potential bubble unwind in AI-linked tech and bulls aggressively trading the frequent, large-scale V-shaped recovery patterns.

Cartesian Growth Corp. III is a blank check company. It was created for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on October 29, 2024 and is headquartered in New York, NY.

Factorial Energy Inc. - Ordinary Shares- Class A

Factorial Energy is experiencing intense market volatility driven by its recent SPAC listing and low public float, sparking high retail interest and frequent trading halts. Investors are actively debating the potential for long-term growth from its solid-state battery technology against concerns over share dilution and the speculative nature of the stock's parabolic price swings.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp (UEC) is trending as investors focus on the company's production ramp-up at its Burke Hollow and Christensen Ranch projects amidst the broader nuclear energy sector's role in powering AI data centers. While the community is actively debating the stock's recent price volatility and institutional activity, sentiment remains heavily tied to the company's debt-free balance sheet and its strategic positioning within the domestic nuclear fuel supply chain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet

The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 57% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 62.5% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Nuvectis Pharma (NASDAQ:NVCT) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04...

Nuvectis Pharma (NVCT) Projected to Post Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-nuvectis-pharma-inc-stock...

Nuvectis Pharma, Inc. $NVCT Shares Acquired by Iridian Asset Management LLC CT

Iridian Asset Management LLC CT increased its holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) by 44.5% during the fourth quarter, according to its most recent filing with the Securities...

Nuvectis Pharma (NASDAQ:NVCT) Trading Down 1.7%  - Here's What Happened

Nuvectis Pharma (NASDAQ:NVCT) Shares Down 1.7% - What's Next...

Nuvectis Pharma (NASDAQ:NVCT) Shares Up 6.3% - Still a Buy?

Nuvectis Pharma (NASDAQ:NVCT) Shares Up 6.3% - Still a Buy...

Nuvectis Pharma (NVCT) to Release Quarterly Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) will be releasing its Q4 2025 earnings before the market opens on Tuesday, February 24. (View Earnings Report at...

HC Wainwright Forecasts Weaker Earnings for Nuvectis Pharma

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Stock analysts at HC Wainwright reduced their FY2026 earnings estimates for Nuvectis Pharma in a research report issued on Wednesday, February...

HC Wainwright Predicts Nuvectis Pharma Q1 Earnings

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Nuvectis Pharma in a research note issued on Wednesday, February 11th. HC...

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its product pipeline includes NXP800 and NXP900. The company was founded by Ronald E. Bentsur, Enrique Poradosu, and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.26	--	--	N/A
Q1 '26	-$0.31	-$0.26	17.20%	BEAT
Q4 '25	-$0.32	-$0.31	1.90%	BEAT
Q3 '25	-$0.25	-$0.44	-76.00%	MISSED
Q2 '25	-$0.25	-$0.30	-19.21%	MISSED

NVCTNuvectis Pharma Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest NVCT News